Article: Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

Related products

• 

  Article: Calendar of events

  €2.42 Add to cart
• 

  Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

  €2.42 Add to cart
• 

  Article: Highlights in breast cancer

  €2.42 Add to cart
• 

  Article: INTRODUCTION

  €2.42 Add to cart